Portfolio Strategy
The current situation
Selecting a preclinical drug candidate to advance to clinical trials is a critical decision. If choices made at this stage are less than ideal, substantial effort and resources can be lost. Likewise, choosing the best patient group for testing new treatments is important. Identifying patient subgroup(s) in which efficacy is likely to be heightened can set the tone for a successful drug development program.
The Archimedes Model offers a high-value, low-cost way to predict the long-term health and cost outcomes of your preclinical pipeline candidates. By harnessing the predictive power of early research data and biomarker effects, Archimedes can explore the impact of new or hypothetical treatments.
Using Archimedes, researchers can anticipate outcomes that would be too resource-intensive to study in the real world, and advance the right drugs to clinical trials.
The Archimedes advantage
The Archimedes Model is a comprehensive, validated simulation and analytical model containing the best available scientific knowledge about human physiology, diseases, clinical care interventions, patient and physician behaviors, and healthcare systems.
The Model can help companies identify and prioritize candidate drugs that have the greatest chance of success.
Using Archimedes, your team can run simulated clinical trials to forecast the effect of pipeline drugs on downstream health outcomes and costs – with greater speed and efficiency than would otherwise be possible, and without recruiting a single patient.
How you can use the Archimedes Model
ARCHeS. ARCHeS is an online healthcare analysis and visualization tool that enables organizations to leverage public, proprietary, and simulation data. ARCHeS provides desktop access to the Archimedes Model, to examine treatments and outcomes related to the following conditions: chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, diabetes and its complications, dyslipidemia, hypertension, metabolic syndrome, obesity, smoking, and stroke.
Researchers can use ARCHeS to simulate multiple scenarios involving different assumptions. These results can be analyzed for different target populations and clinical endpoints.
Through a partnership with Quintiles, our customers have access to a large pool of expertise and global capabilities. When you combine expert opinion with data from the Archimedes Model, you have a robust platform for developing a portfolio strategy.
Modeling & Consulting Services. For diseases and interventions beyond the scope of ARCHeS, Archimedes provides comprehensive support to help you run custom simulations. Our team of scientists and physicians will work with you to develop your objectives, forecast the impact of new products on outcomes of interest, analyze and interpret data, and make concrete portfolio recommendations.
